Rapid Antimanic Effect of Risperidone Monotherapy: A 3-Week Multicenter, Double-Blind, Placebo-Controlled Trial
American Journal of PsychiatryPublished 28 May 2004
Robert M. A. Hirschfeld, Paul E. Keck, Michelle Kramer, Keith Karcher, Carla M. Canuso, Mariëlle Eerdekens
Citations258
SJR quartileQ1
SJR score5.27
SNIP3.68
Generate an AI Snapshot to get a quick, structured summary of this paper.
Study Snapshot
ObjectiveStudy objective
MethodsResearch methodology
PopulationPopulation studied
Sample sizeSample sizes
OutcomesStudy outcomes here
ResultsStudy results comes here
LimitationsResearch study limitations comes here
A concise AI-generated summary of the paper will appear here once you click Generate AI Snapshot.
TL;DR
Risperidone monotherapy was significantly more efficacious than placebo in the treatment of acute mania and demonstrated a rapid onset of action.
Abstract
Risperidone monotherapy was significantly more efficacious than placebo in the treatment of acute mania and demonstrated a rapid onset of action. Risperidone was well tolerated by patients in this study.
Keywords
Medicine
Schizophrenia BulletinThe Positive and Negative Syndrome Scale (PANSS) for Schizophrenia
21,398 Citations1987Stanley R. Kay, Abraham Fiszbein +1 more
Review of five studies involving the PANSS provided evidence of its criterion-related validity with antecedent, genealogical, and concurrent measures, its predictive validity, its drug sensitivity, and its utility for both typological and dimensional assessment.
The British Journal of PsychiatryA New Depression Scale Designed to be Sensitive to Change
13,927 Citations1979Stuart Montgomery, Marie Åsberg
The construction of a depression rating scale designed to be particularly sensitive to treatment effects is described, and its capacity to differentiate between responders and non-responders to antidepressant treatment was better than the HRS, indicating greater sensitivity to change.
The British Journal of PsychiatryA Rating Scale for Mania: Reliability, Validity and Sensitivity
8,738 Citations1978Robert C. Young, John T. Biggs +2 more
The MRS score correlated highly with an independent global rating, and with scores of two other mania rating scales administered concurrently, and also correlated with the number of days of subsequent stay in hospital.
Archives of General PsychiatryThe Global Assessment Scale
4,952 Citations1976Jean Endicott
The relative simplicity, reliability, and validity of the GAS suggests that it would be useful in a wide variety of clinical and research settings.
BiometricsSequential Treatment Assignment with Balancing for Prognostic Factors in the Controlled Clinical Trial
2,302 Citations1975Stuart Pocock, Richard Simon
A new general procedure for treatment assignment is described which concentrates on minimizing imbalance in the distributions of treatment numbers within the levels of each individual prognostic factor.
Archives of General PsychiatryThe Structured Clinical Interview for DSM-III-R (SCID)
1,627 Citations1992Janet B. W. Williams
A test-retest reliability study of the Structured Clinical Interview for DSM-III-R was conducted on 592 subjects in four patient and two nonpatient sites in this country as well as one patient site in Germany.
The Journal of Clinical PsychiatryScreening for Bipolar Disorder in the Community
672 Citations2003Robert M. A. Hirschfeld, Joseph R. Calabrese +9 more
The positive MDQ screen rate of 3.7% suggests that nearly 4% of American adults may suffer from bipolar I and II disorders, and young adults and individuals with lower income are at greater risk for this largely underdiagnosed disorder.
American Journal of PsychiatryOlanzapine Versus Placebo in the Treatment of Acute Mania
570 Citations1999Mauricio Tohen, T.M. Sanger +13 more
The olanzapine group experienced significantly greater mean mean scores than the placebo group in the treatment of acute mania, and the primary efficacy measure was defined as a change from baseline to endpoint in total score on the Young Mania Rating Scale.
Archives of General PsychiatryEfficacy of Olanzapine in Acute Bipolar Mania<subtitle>A Double-blind, Placebo-Controlled Study</subtitle>
543 Citations2000Mauricio Tohen
Olanzapine demonstrated greater efficacy than placebo in the treatment of acute bipolar mania and was generally well tolerated.
American Journal of PsychiatryA Placebo-Controlled, Double-Blind Study of the Efficacy and Safety of Aripiprazole in Patients With Acute Bipolar Mania
502 Citations2003Paul E. Keck, Ronald N. Marcus +6 more
Aripiprazole had significantly greater efficacy than placebo for the treatment of bipolar disorder patients in acute manic or mixed episodes and was safe and well tolerated in this randomized controlled trial.
American Journal of PsychiatryCombination of a Mood Stabilizer With Risperidone or Haloperidol for Treatment of Acute Mania: A Double-Blind, Placebo-Controlled Comparison of Efficacy and Safety
410 Citations2002Roy H. Perlis, Fred Grossman +3 more
Risperidone plus a mood stabilizer was more efficacious than a mood stabilizeizer alone, and as efficacious as haloperidol plus a Mood stabilizer, for the rapid control of manic symptoms and was well tolerated.
American Journal of PsychiatryZiprasidone in the Treatment of Acute Bipolar Mania: A Three-Week, Placebo-Controlled, Double-Blind, Randomized Trial
372 Citations2003Paul E. Keck, Márcio Versiani +5 more
Ziprasidone monotherapy was significantly superior to placebo in reducing symptoms of acute mania in patients with bipolar I disorder.
PubMedBindingDB Entry 4838: Risperidone: a novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity.
335 Citations2011J.E. Leysen
It was observed that antagonism of strong D2-receptor stimulation by apomorphine in rats was achieved at less than 50% D2 occupancy by the antipsychotics, and the ex vivo receptor occupancy profile of the compounds matched the in vitro receptor binding profile.
The LancetBipolar disorder
329 Citations2002B. Müller‐Oerlinghausen, Anne Berghöfer +1 more
The authors in the context of the Wider NIMH Affective Disorders Workgroup propose several specific recommendations to address the needs of this costly and underresearched disorder.
Journal of Clinical PsychopharmacologyProlactin Levels and Adverse Events in Patients Treated with Risperidone
306 Citations1999David L. Kleinberg, John M. Davis +3 more
This analysis was designed to characterize the relationship between the use of antipsychotic agents and hyperprolactinemia in men and the likelihood of sexual dysfunction.
PubMedRisperidone compared with both lithium and haloperidol in mania: a double-blind randomized controlled trial.
238 Citations1998Jose Segal, Michael Berk +1 more
Risperidone is of equivalent efficacy to lithium and haloperidol in the management of acute mania and the Global Assessment of Functioning and Clinical Global Impression data showed a similar pattern of improvement.
The Journal of Clinical PsychiatryRisperidone Safety and Efficacy in the Treatment of Bipolar and Schizoaffective Disorders
123 Citations2001Eduard Vieta, José Manuel Goikolea +8 more
This large study provides additional evidence that risperidone is effective and well tolerated when combined with mood stabilizers in the treatment of bipolar disorder and schizoaffective disorder, bipolar type.
European Journal of Pharmacologyα2C-Adrenoceptor blockade by clozapine and other antipsychotic drugs
87 Citations2003Hans O. Kalkman, Erika Loetscher
The antagonistic potencies of the antipsychotics clozapine, chlorpromazine, risperidone, olanzapines, haloperidol, quetiAPine, ziprasid one, iloperidone and aripiprazole were quantified and it was hypothesised that alpha(2C)-adrenoceptor blockade contributes to improvement of cognitive function.
Medical Clinics of North AmericaBIPOLAR DISORDER
60 Citations2001Paul E. Keck, Susan L. McElroy +1 more
PubMedDopaminergic deficit and mood disorders.
27 Citations2002Luca Pani, Gian Luigi Gessab
An overview of the animal data that demonstrate the importance of dopamine in animal behaviour and suggest that dopaminergic deficiency may cause a number of psychiatric symptoms in man are provided.
European NeuropsychopharmacologyP.2.152 Ziprasidone in mania: A 21-day randomized, double-blind, placebo controlled trial
7 Citations2003Scott Segal, Robert Riesenberg +2 more